CHILDREN'S ALLEGRA ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ALLEGRA ALLERGY (CHILDREN'S ALLEGRA ALLERGY).
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
| Metabolism | Minimally metabolized; approximately 5% undergoes hepatic metabolism via CYP3A4. Primarily excreted unchanged in feces and urine. |
| Excretion | Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion. |
| Half-life | Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing. |
| Protein binding | Plasma protein binding: 60–70%, primarily to albumin. |
| Volume of Distribution | Volume of distribution: approximately 5.4–5.8 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability: approximately 33% (varies with food; administration with apple or orange juice decreases absorption). |
| Onset of Action | Oral: onset of action occurs within 1 hour for allergy symptom relief. |
| Duration of Action | Oral: duration of action is approximately 24 hours, supporting once-daily dosing. |
| Molecular Weight | 501.77 |
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | CrCl < 80 mL/min: 60 mg once daily. CrCl < 15 mL/min: Use not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment. Severe hepatic impairment: Insufficient data, use caution. |
| Pediatric use | 2-11 years: 30 mg twice daily; 12 years and older: 60 mg twice daily or 180 mg once daily. |
| Geriatric use | Starting dose 60 mg once daily based on renal function; monitor for increased sensitivity. |
| 1st trimester | Limited human data; animal studies not suggestive of harm. Use only if clearly needed. |
| 2nd trimester | Limited human data; no known risk based on available evidence. |
| 3rd trimester | Limited human data; no known risk of fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ALLEGRA ALLERGY (CHILDREN'S ALLEGRA ALLERGY).
| Placental transfer | Fexofenadine crosses the placenta; limited data suggest low transfer. |
| Breastfeeding | Fexofenadine is excreted into breast milk in low amounts (estimated infant dose <1% of maternal weight-adjusted dose). Not expected to cause adverse effects in breastfed infants. Monitor for drowsiness. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to fexofenadine or any component of the formulation
| Precautions | Renal impairment: adjust dose. Avoid use with fruit juices (grapefruit, orange, apple) as they decrease absorption. Caution in elderly and hepatic impairment. |
| Food/Dietary | Avoid concurrent administration with apple, grapefruit, or orange juice as these reduce fexofenadine absorption by up to 36% (apple), 20% (grapefruit), and 39% (orange). Do not take with aluminum- or magnesium-containing antacids; separate by at least 2 hours. No significant interaction with food other than fruit juices; however, taking with a high-fat meal may slightly delay absorption but does not significantly affect overall exposure. |
Loading safety data…
| L2 |
| Teratogenic Risk | Fexofenadine is classified as FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 3 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk. Second and third trimesters: Limited human data suggest no increased risk of major malformations; however, caution is advised. |
| Fetal Monitoring | No specific monitoring is required for fexofenadine use during pregnancy; however, standard prenatal care should be maintained. Observe for maternal adverse effects such as drowsiness (though fexofenadine is less sedating than older antihistamines) and monitor fetal growth and development as per routine obstetrical practice. |
| Fertility Effects | Animal studies have not shown significant effects on fertility at therapeutic doses. In humans, there are no adequate studies on fexofenadine's impact on fertility. Based on its antihistamine activity, it is not expected to interfere with reproductive function, but caution is warranted in women attempting conception. |
| Clinical Pearls | For children aged 2-11 years with seasonal allergic rhinitis or chronic idiopathic urticaria, CHILDREN'S ALLEGRA ALLERGY (fexofenadine) is a second-generation antihistamine that is nonsedating and has minimal anticholinergic effects. It does not require dose adjustment for mild-to-moderate hepatic impairment but requires adjustment for severe renal impairment (CrCl <15 mL/min): 30 mg once daily. Do not administer with aluminum- or magnesium-containing antacids as they decrease absorption; separate by at least 2 hours. Fruit juices (apple, grapefruit, orange) reduce bioavailability; avoid concurrent administration. For children <2 years, safety not established. |
| Patient Advice | Take this medication exactly as prescribed; do not exceed the recommended dose. · For best results, take on an empty stomach with water, and avoid fruit juices (apple, grapefruit, orange) within 2 hours of dosing. · Do not take with antacids that contain aluminum or magnesium; separate by at least 2 hours. · This medication may cause drowsiness in some children; observe for sedation, especially when starting therapy. · Do not use for more than 2 weeks for hives without consulting a healthcare provider. · Store at room temperature, away from moisture and heat. · Contact a healthcare provider if symptoms persist or worsen. · Keep out of reach of children. |